DoJ issues subpoena related to Avandia

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it is in the process of responding to a subpoena from the U.S. Department of Justice related to the development and marketing of diabetes drug Avandia rosiglitazone. The pharma said it also received Civil Investigative Demands from several States Attorneys General offices related to Avandia. The pharma would not disclose further information, except to say that the "enquiries are at an early-stage and GSK is cooperating with these offices." Last month, FDA significantly restricted the use of Avandia while EMA suspended the drug's marketing authorization due to cardiovascular safety concerns. ...